Abstract: A system and method of determining a depth map sequence for a subject two-dimensional video sequence by: determining a plurality of monocular depth cues for each frame of the subject two-dimensional video sequence; and determining a depth map for each frame of the subject two-dimensional video sequence based on the application of the plurality of monocular depth cues determined for the frame to a depth map model. The depth map model determined by: determining a plurality of monocular depth cues for one or more training two-dimensional video sequences; and determining a depth map model based the plurality of monocular depth cues of the one or more training two-dimensional video sequences and corresponding known depth maps for each of the one or more training two-dimensional video sequences.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: A Raman spectrometer system provides a tool for discriminating between different tissue pathologies. The tool may provide discrimination indicators for a plurality of different pairs of tissue pathologies. Improved sensitivity and specificity are achieved by basing discriminations on appropriate ranges within a Raman spectrum.

Abstract: The present invention provides methods of detecting mutations in a GNA11 gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated GNA11 gene.

Abstract: Sunlight redirector (30) incorporates closely proximate mirror arrays (32, 34) having parallel, uniformly spaced, longitudinal mirror segments (38, 44). Prismatic sheet (36) is positioned behind and closely proximate second array (34). Segments (38) extend in first direction (x). Segments (44) extend in second direction (y) perpendicular to direction (x) segments (38, 44)have normal vectors (42, 48). Segments (38) are interconnected for simultaneous pivotal movement (40), such that their normal vectors (42) remain parallel. Segments (44) are interconnected for simultaneous pivotal movement (46), such that their normal vectors (48) remain parallel. Arrays (32, 34) redirect incident light toward sheet (36), which redirects the light into a desired fixed direction, e.g. parallel to the sunlight redirect's normal vectors (50). Segments (38, 44) may have inward and outward segments (60A, 60B) which can be adjustably positioned to maximize redirection of incident sunlight rays in a desired direction.

Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.

Abstract: Isolated polynucleotides comprising an S100B promoter are provided, where an S100B regulatory element is operably joined to an S100B basal promoter utilizing a non-native spacing between the promoter and regulatory elements. The promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.

Abstract: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediaminetetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.

Abstract: Provided herein are diterpene synthases (diTPS) and methods for producing diterpenoids. Also provided herein are nucleic acid sequences encoding diTPS, diTPS amino acid sequences, diTPS proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.

Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

Abstract: The embodiments described herein relate generally to an elastography method and system for obtaining ultrasound images of an excited tissue over a certain time period, then computationally determining one or more mechanical properties of the tissue within a real time refresh rate. This method can perform elastography in real time as only a thin volume of the excited tissue is imaged and processed. The thin volume includes a desired cross-sectional plane of the tissue and at least two adjacent planes that are adjacent to the desired cross-sectional plane. A maximum number of adjacent planes is selected so that a computer system is capable of computationally determining mechanical properties within a real time refresh rate.

Abstract: Particles of interest such as DNA, RNA may be detected in trace quantities by subjecting the particles to concentration by scodaphoresis, detecting a signal indicative of the presence of the particles in a scodaphoresis focus spot and performing phase-sensitive detection on the signal using a reference signal tied to the scodaphoresis fields. Specificity may be enhanced by using a medium having high affinity for the particles and/or markers having specific affinity for the target particles. In some embodiments a fluorescence signal is detected and subjected to phase-sensitive analysis. The signal may be detected by a camera or other imaging system.

Abstract: Devices for treating a bone and methods of inserting such devices into a bone are disclosed. A device for treating a bone may include a flexible tube, a stiffening mechanism and an actuator. The flexible tube has a distal end and a proximal end. The stiffening mechanism within the flexible tube is configured to cause the flexible tube to become rigid. The actuator is configured to cause the stiffening mechanism to cause the flexible tube to become rigid in response to the actuator being actuated.

Abstract: Particles may be injected into a matrix for concentration by scodaphoresis using a quadrupole injection field. Particles may be injected from two or more sample chambers simultaneously. Particle injection may be performed simultaneously with performing scodaphoresis. In some embodiments the particles are concentrated into a well containing fluid. The well can extend out of a plane of the matrix. Altering the relative phases of components of a scodaphoresis field permits concentration of selected particles and exclusion of other particles. Scodaphoresis methods may be applied to DNA, other bio-molecules and other particles.

Abstract: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.

Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.

Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.

Abstract: Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under the GH34 family of viral enzymes.

Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.

Abstract: A method of recovering copper from chalcopyrite concentrate by chemical leaching, using pyrite and silver. The catalytic properties of pyrite in the chalcopyrite leaching process are significantly enhanced by pretreating the pyrite with silver ions. Particulate pyrite is exposed to a solution containing silver ions to form silver-treated pyrite. Particulate chalcopyrite and the silver-treated pyrite are mixed in an acidic sulfate leach solution. The copper is leached from the concentrate in the leach solution in the presence of an oxygen-containing gas, under conditions whereby the pyrite is substantially unoxidized. The leached copper is recovered from the solution by conventional methods. The used silver-treated pyrite is recycled to the leaching process.